Learn more about our unprecedented approach,
from problem to our solution.
Glioblastoma
is the most common and aggressive malignant primary brain tumour.
40,000 new cases per year globally
GBM tumours are difficult to treat
Considered incurable
Nearly 100% of patients experience disease relapse after initial treatment
Current standard of care
is of limited benefit and prognosis is poor
Surgery, Chemotherapy and Radiotherapy
There are 4 approved therapies which have had minimal impact on survival – TMZ the only therapy to demonstrate OS benefit (2.5 months)
Average survival after diagnosis is 15 months
Our solution: differentiation therapy
Paradigm shift in treating brain cancer
Differentiation therapy turns cancer stem cells into “normal”, mature brain cells, thereby rendering them unable to multiply and incapable of perpetuating the tumor
A platform technology leveraging neurobiology of brain stem cells to discover biological drugs that specifically tackle tumor cells, particularly aggressive cancer stem cells.
The strength of our approach
Distruptive discovery Platform
An unprecedented approach in the field of solid tissue cancers
Overcames flaws in drug discovery
responsible for repeated failures in neurocology
Pipeline of unconventional and innovative leads
Standard drug development time reduced by ten folds
A distruptive discovery and validation platform
Brain Cancer Stem Cell
Primary Lines
Surgery Tissue
Samples
Definition of new Leads
Data Analysis and Data Quering
Differentional Functional Conditions
Predictive Canditates
Validation
Golden Canditates
Golden Candidates
Agonism/Antagonism Strategies
DISCOVERY MODULE
Our Platform is based on the largest collection of brain primary cancer and normal stem cell lines.
By proprietary assays it discovers and validates new leads that tackle specific cell functions in cancer-initiating cells with unprecedented, unmatched prediction ability